Mechanisms of action of GLP-1RA
US$ 29.44
ofa lawsuit tirzepatide A class-action has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients Lilly seeks to intervene in
Description
Compounded formulations may not follow the standard tirzepatide dosing chart used with FDA-approved versions
Chemically, tirzepatide is a peptide, which is essentially a short chain of amino acids
Lillys CEO Dave Ricks warned that the growth of compounding could create a backdoor generic world. This article is exclusive to STAT+ subscribers Unlock this article plus daily coverage and analysis of the pharma industry by subscribing to STAT+
The FDA has been tightening enforcement as shortages resolve
